Sign Up Today and Learn More About BostonGene Stock
Invest in or calculate the value of your shares in BostonGene or other pre-IPO companies through EquityZen's platform.
BostonGene Stock (BOGE)
BostonGene is a biomedical software company for advanced patient analysis and personalized therapy in the fight against cancer.
About BostonGene Stock
Founded
2015
Headquarters
Waltham, MA, US
Industries
Software, Data and Analytics, Science and Engineering
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies
BostonGene Press Mentions
Stay in the know about the latest news on BostonGene
Systems and methods for analyzing cytometry data
patents • May 04, 2025
Flow cytometry immunoprofiling of peripheral blood
patents • May 04, 2025
Cytokine gene expression signatures
patents • May 04, 2025
Machine learning techniques for cytometry
patents • May 04, 2025
BostonGene Appoints Dr. Ferran Prat as Chief Commercial Officer
citybiz • Apr 09, 2025
BostonGene Management
Leadership team at BostonGene
President & CEO
Andrew Feinberg
Join now and verify your accreditation status to gain access to:
- BostonGene Current Valuation
- BostonGene Stock Price
- BostonGene Management
- Available deals in BostonGene and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- BostonGene Cap Table and Funding History by Share Class and Liquidity Preferences
- BostonGene Revenue and Financials
- BostonGene Highlights
- BostonGene Business Model
- BostonGene Risk Factors
- BostonGene Research Report from SACRA Research
Trading BostonGene Stock
How to invest in BostonGene stock?
Accredited investors can buy pre-IPO stock in companies like BostonGene through EquityZen funds. These investments are made available by existing BostonGene shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell BostonGene stock?
Shareholders can sell their BostonGene stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
